Distribution of Rifampicin-Resistant Tuberculosis Patients based on Presumptive Drug-Resistant Tuberculosis Criteria at Dr. Hasan Sadikin Hospital 2016–2019

Authors

  • Dinda Nursyafira Misyatin Faculty of Medicine Universitas Padjadjaran
  • Arto Yuwono Soeroto Departement of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
  • Ferdy Ferdian Departement of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung

DOI:

https://doi.org/10.15850/amj.v9n4.2593

Keywords:

Presumptive DR-TB criteria, tuberculosis, Xpert MTB/RIF Ct values

Abstract

Background: Diagnosis of drug-resistant tuberculosis (DR-TB) begins with identifying presumptive DR-TB patients using Xpert MTB/RIF, as a diagnostic test to detect resistance to rifampicin. The study aimed to identify the distribution of rifampicin-resistant tuberculosis (RR-TB) patients based on presumptive DR-TB criteria at Dr. Hasan Sadikin General Hospital Bandung. Moreover, this study also explored the Xpert MTB/RIF Ct values.

Methods: This was a descriptive-retrospective study from 570 medical records of DR-TB patients collected at the Multidrug-resistant tuberculosis (MDR-TB) clinic of Dr. Hasan Sadikin General Hospital from 2016 to 2019. The inclusion criteria were suspected patients with the Xpert MTB/RIF Ct values in the very low-low and medium-high categories. Data were analyzed using frequency distribution.

Results: The most common presumptive DR-TB criteria among DR-TB patients were relapse cases (52.3%). Presumptive DR-TB criteria, with a high percentage result of medium-high Ct values, were category II treatment failure (80.9%).

Conclusion: Relapse case and category II treatment failure are presumptive DR-TB criteria, which need more attention from clinicians.

References

  1. World Health Organization. Global tuberculosis report. Geneva, Switzerland: WHO; 2019.
  2. Management Sciences for Health. e-TB manager: report TB06 [internet]. [Cited 2020 October 13]. Available from: etbmanager.sitb.id
  3. Ministry of Health Republic of Indonesia. Minister of Health Decree No. 67/2016 about Tuberculosis Control. Jakarta: Ministry of Health Republic of Indonesia; 2016.
  4. Fradejas I, OntañónB, Muñoz-gallegoI, Ramirez-Vela MJ, López-Roa P. The value of xpert MTB/RIF-generated CT values for predicting the smear status of patients with pulmonary tuberculosis. J Clin Tuberc Other Mycobact Dis. 2018;13:9–12.
  5. Sabiiti W, Azam K, Farmer ECM, Kuchaka D, Mtafya B, Bowness R, et al. Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis molecular bacterial load assay. Thorax. 2020;75:606–8.
  6. van Kampen SC, Susanto NH, Simon S, Astiti SD, Chandra R, Burhan E, et al. Effects of introducing Xpert MTB/RIF on diagnosis and treatment of drug-resistant tuberculosis patients in Indonesia: a pre-post intervention study. PLoS One. 2015;10(6):e0123536.
  7. Khann S, Mao ET, Rajendra YP, Satyanarayana S, Nagaraja SB, Kumar AMV. Linkage of presumptive multidrug resistant tuberculosis ( MDR-TB ) patients to diagnostic and treatment services in Cambodia. PLoS One. 2013;8(4):e59903.
  8. Gautam PB, Mishra A, Kumar S. Prevalence of rifampicin resistant mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients in eastern Uttar Pradesh: a cross sectional study. Int J Community Med Public Health. 2018:5(6):2271–6.
  9. Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infect Dis. 2020;20(1):789.
  10. Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? BMC Infect Dis. 2017;17(1):36.
  11. Trinh QM, Nguten HK, Nguyen VN, Nguyen TVA, Sintchenko V, Brais BJ. Tuberculosis and HIV co-infection-focus on the Asia-Pacific region. Int J Infect Dis. 2015;32: 170–8.
  12. Liu Y, Zhang XX, Yu JJ, Liang C, Xing Q, Yao C, et al. Tuberculosis relapse is more common than reinfection in Beijing, China. Infect Dis (Lond). 2020;52(12):858–65.
  13. Najjingo I, Muttamba W, Kirenga BJ, Nalunjogi J, Bakesiima R, Olweny F, et al. Comparison of GeneXpert cycle threshold values with smear microscopy and culture as a measure of mycobacterial burden in five regional referral hospitals of Uganda- A cross-sectional study. PLoS One. 2019;14(5):e0216901.
  14. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva, Switzerland: WHO; 2017.
  15. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glazio P, Flyod K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010. Bull World Health Organ. 2012; 90(2):111–9D.
  16. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children-Policy update. Geneva, Switzerland: WHO Press; 2013.
  17. Soeroto AY, Lestari BW, Santoso P, Chaidir L, Andriyoko B, Alisjahbana B, et al. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study. PLoS One. 2019;14(2):e0213017.
  18. Nuraeni N, Suryadinata H, Lestari BW. Geographical factors in diagnostic delay among multidrug resistant tuberculosis patients. Althea Med J. 2017;4(3):444–8
  19. Ramadhani AR, Lestari BW, Suryadinata H. Knowledge toward drugs resistant tuberculosis in one of the highest burden drug resistant country. Althea Med J. 2018;5(3):127–32
  20. Htun YM, Khaing TMM, Aung NM, Yin Y, Myint Z, Aung ST, et al. Delay in treatment initiation and treatment outcomes among adult patients with multidrug-resistant tuberculosis at Yangon Regional Tuberculosis Centre, Myanmar: a retrospective study. PLoS One. 2018;13(12): e0209932.
  21. Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: a retrospective cohort study. PLoS One. 2021;16(2): e0246284.

Downloads

Published

2022-12-31

Issue

Vol. 9 No. 4 (2022)

Section

Articles

License

  1. Authors retain copyright and grant Althea Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to freely share and remix the work with an acknowledgement of the work's authorship and initial publication in Althea Medical Journal. Althea Medical Journal is licensed under CC BY-NC 4.0
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Althea Medical Journal.